Innoviva Financial Ratios
NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Innoviva ratio analysis
Innoviva earned a net margin of 65.9% in FY 2025, up from 6.5% a year earlier. Gross margin was 74.8% compared with a median of 80.9% over the prior 2 years. Return on equity reached 23.1%, meaning Innoviva generated 0.23 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.22 versus 0.65 the year before, and the current ratio was 14.64. At the end of FY 2025, INVA traded at 6.0 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 5.1 to 48.7, with a median of 6.7. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Innoviva financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 6.02 | 48.67 | 7.29 | 5.59 | 6.01 | 6.13 | 9.72 | 5.05 | 12.13 | 20.19 |
| Price / sales | 3.26 | 3.06 | 3.38 | 2.79 | 3.61 | 3.73 | 5.39 | 6.89 | 6.99 | 8.83 |
| Price / book | 1.14 | 1.59 | 1.56 | 1.63 | 3.41 | 2.33 | 4.48 | 11.71 | — | — |
| Gross margin | 74.8% | 82.6% | 79.2% | — | — | — | — | — | — | — |
| Operating margin | 39.8% | 46.5% | 36.7% | — | 95.7% | 95.3% | 94.4% | 91.3% | 84.5% | 81.6% |
| Net margin | 65.9% | 6.5% | 57.9% | 66.5% | 94.1% | 87.2% | 73.2% | 155.7% | 61.8% | 44.6% |
| Free cash flow margin | 47.6% | 52.5% | 45.3% | 60.9% | 92.8% | 93.0% | 98.6% | 85.6% | 65.3% | 45.4% |
| Return on equity (ROE) | 23.1% | 3.4% | 26.6% | 38.9% | 88.9% | 54.4% | 60.9% | 264.6% | — | — |
| Return on assets (ROA) | 16.6% | 1.8% | 14.5% | 17.9% | 39.8% | 29.4% | 26.4% | 74.1% | 36.6% | 15.7% |
| Debt / equity | 0.22 | 0.65 | 0.66 | 0.96 | 0.95 | 0.71 | 1.20 | 2.49 | — | — |
| Current ratio | 14.64 | 2.35 | 9.03 | 3.29 | 54.02 | 55.98 | 80.29 | 34.92 | 5.77 | 9.88 |
| Revenue growth | 14.7% | 15.5% | -6.3% | -15.4% | 16.4% | 29.0% | 0.0% | 20.2% | 62.6% | 147.6% |
| EPS growth | 816.7% | -83.6% | -7.2% | -17.4% | 42.1% | 41.3% | -59.5% | 201.7% | 120.8% | — |